Decoding MicrobiomeRevolutionising Treatment
GutSee Health is developing breakthrough precision medicine therapies that re-engineer the gut ecosystem to transform the treatment of chronic gut disorders such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). By combining microbiome engineering with phage technology, we aim to achieve what existing therapies cannot: lasting, targeted restoration of gut health.
At the core of our work is a proprietary AI discovery platform that mines the human gut for therapeutic insights. By integrating multi-omics data with advanced AI modelling, we identify key microbiome interactions, metabolic disruptions, and the biological pathways that drive disease.
Through our PhageX project, we are building sophisticated machine learning models to decode phage–bacteria interactions and predict therapeutic responses. This enables us to design targeted interventions that remove harmful or pro-inflammatory microbes—whether in the gut or in wounds—while preserving healthy ecosystems.
Our vision is bold but simple: to make precision microbiome therapies accessible, scalable, and life-changing, setting a new standard for bacteria led diseases worldwide.
Our OfferingBespoke AIDiscovery platform
Hundreds of millions of people have gut disorders globally with Irritable Bowel Syndrome affecting over 62 million people in the USA alone. GutSee is revolutionising the future of treating gut disorders by using cutting-edge science with AI modelling.
Our revolutionary AI Discovery platform enables complex analyses of Big-Data and AI modelling revealing the molecular signature behind gut disorders, starting with Irritable Bowel Syndrome (IBS). Disrupted gut ecosystem can be rebalanced removing all IBS symptoms by using our microbiome therapy that reverts it back to health.
Effectiveness
Struggling to ensure your drug’s efficacy? Unlock better outcomes with targeted strategies.
Acceleration
Speed up pharmacokinetics research for faster, more accurate drug development breakthroughs.
Microbiome
Understand how the microbiome impacts drug pharmacokinetics for improved precision.
Selection
Optimise patient selection in clinical trials to enhance drug evaluation accuracy.
VideoAn Introduction
Our Solution
TargetedMicrobiome Therapy
A disrupted gut ecosystem (e.g. dysbiotic microbiome) is implicated in many gut disorders, including Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). These diseases affect over 10 million patients in the UK, leading to 1.5-2 million workdays lost annually and costing the NHS £2 billion annually. There is currently no curative treatment for Irritable Bowel Syndrome, and existing symptom management solutions fail 40-60% of patients.
GutSee is a science-first company developing cutting-edge, targeted precision phage-biotic therapy aimed at re-engineering the disrupted gut microbiome & ecosystem, addressing the root causes of gut diseases.
The therapy uses a dual-pronged approach:
    ADD missing and therapeutic bacteria
    REMOVE harmful bacteria using targeted phages
62m+
IBS sufferers in USA
100m+
Global Gut disorder sufferers
15%
Proportion of UK affected by IBS
Team
Professor Samuel Livingstone
Technical Advisor
Dr Timothée Stumpf-Fétizon
Principle Machine Learning Engineer
Dr Mark Preston
CTO
Professor Charlie Lees
CMO
Cezary Wereszko
CFO & Defence Lead
Jake Bowden
Bioinformatics and Data Scientist
Dr Joanna Wiecek
CEO
Josefina Cid
Senior Scientist
